88 DESMOPRESSIN THERAPY FOR ENURESIS

Abstract

To determine the effectiveness of desmopressin (DDAVP, a vasopressin analogue) for treating enuresis, we performed a double-blind crossover study at three medical centers. Subjects (N=43) ranged from 6 to 16 years old, had normal renal function and denied polyuria, polydipsia and daytime incontinence. The study encompassed four consecutive two-week periods: pre-treatment, treatment with placebo or DDAVP (40 mcg intranasally at 8 PM), crossover treatment, and post-treatment. DDAVP did not produce adverse side effects or significantly alter blood pressure, body weight, serum osmolality or urine osmolality. The results were as follows:Thirteen of 43 children responded to DDAVP (number of wet nights <6). In 6 of the responders, the drug effect persisted into the next study period. Only 2 of 24 children responded to placebo during the first treatment period. In conclusion, DDAVP appears safe for treating enuresis. A child's response to the drug can be determined by a two-week therapeutic trial.